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Abstract
There is increasing evidence of a connection between hearing function and myasthenia gravis (MG).
Studies of the pathophysiological basis of this relationship suggest that acetylcholine receptors
(AChRs) on outer hair cells (OHCs) play a central role. In patients with MG, autoantibodies against
AChRs induce a progressive loss of AChRs on OHCs, decreasing their electromotility. The
stapedial reflex decay test can be altered in MG patients, and can be used as an additional tool for
diagnosis and monitoring. Transient evoked and distortion product otoacoustic emissions are the
main diagnostic tool for monitoring OHC functionality in MG patients, and can be used to record
subclinical hearing alterations before the onset of clinically evident hearing loss. Understanding the
association between MG and hearing dysfunction requires a multidisciplinary approach.
Otolaryngologists should take this relationship into account when approaching patients with a
diagnosis of myasthenia gravis and ‘‘in patients with MG’’ with a˜ in MG patients, and the progress of
hearing alterations should always be monitored in patients with MG.
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DPOAEs distortion product otoacous-
tic emissions
Introduction
Myasthenia gravis (MG) is a condition
causing muscle weakness and fatigue, and is
the most common autoimmune disorder
affecting the neuromuscular junction. The
prevalence of MG in the USA is estimated at
14 to 20 per 100,000 people, with approxi-
mately 36,000 to 60,000 affected individ-
uals.1,2 Deenen3 conducted a comprehensive
review of 24 studies published between 1990
and 2014, reporting that the worldwide
prevalence of MG ranged from 5.35 to 35
per 100,000 people. Although MG can occur
at any age, the age of onset in women is
typically between 20 and 40 years, and the
typical age of onset for men is between 40 to
60 years of age. Epidemiological studies from
Canada and Japan have reported an increas-
ing frequency ofMG among elderly people in
recent decades, possibly because of increased
awareness among medical doctors.4,5
Typical clinical symptoms of MG include
weakness of the facial, ocular, bulbar,
respiratory or limb muscles, worsening
after prolonged muscle usage.6 The primary
mechanism of MG is an antibody-mediated
attack on the proteins of the postsynaptic
membrane, resulting in decreased signal
transmission at the neuromuscular junction.
Antibody mediated attack on acetylcholine
receptors (AChRs) is reported to be
involved in approximately 85% of cases,
while in 5–8% of the cases, muscle-specific
kinase (MuSK) is affected. Lipoprotein
receptor-related protein 4 (LRP-4), also
known as multiple epidermal growth
factor-like domains 7 (MEGF7), is involved
in 5–7% of MG cases.7
A number of studies have investigated the
connection between hearing function and
MG, increasing understanding of the patho-
physiological mechanisms underlying this
relationship.9–11,22 Hearing loss in MG
patients typically presents at a subclinical
stage with abnormal otoacoustic emissions
and pure tone audiometry (PTA) often
within the normal range. One study reported
clinically evident hearing loss with auditory
thresholds higher than 25 dBHL in 30% of
MG patients examined, while all patients in
the sample exhibited abnormal distortion
product otoacoustic emissions (DPOAEs)
and transient evoked otoacoustic emissions
(TEOAEs).10 These techniques have been
found to exhibit greater sensitivity to incipi-
ent cochlear damage than PTA, particularly
for high frequencies.11
A correct diagnosis and management of
hearing disorders in patients with MG
requires a multidisciplinary approach.
Awareness of this connection among neurolo-
gists, otolaryngologists and other specialists
involved in the clinical and research aspects of
MG can aid investigation of hearing function
at first admission and follow up, facilitating
the management of possible hearing dysfunc-
tion. In the current review, we discuss evidence
from studies of hearing function alterations in
patients with MG, focusing on research into
the pathophysiological basis of the effects of
MG on hearing, as well as the clinical diag-
nosis and management of hearing disorder in
these patients.
MG and hearing function
Hearing function and MG:
The role of AChRs
The relationship between MG and hearing
function has been investigated, indicating
that AChRs on outer hair cells (OHCs) play
a central role.10,12,22 In an early immunohis-
tochemical study, Plinkert8 used nicotinic
acetylcholine receptor (nAChR) antibodies
in the cochlea to visualize nAChRs, examin-
ing the development of efferent fibres and
postsynaptic OHC receptors in 13 cochleae
from fetal guinea pigs. The results revealed
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that maturation of postsynaptic nAChRs
coincided with the development of motile
properties of OHCs.8 In healthy subjects,
acetylcholine (ACh), the primary neuro-
transmitter of the efferent auditory system,
has been found to enhance the electromoti-
lity of OHC binding to AChRs, which are
localized on the post-synaptic membrane of
OHCs.9 In patients with MG, autoantibo-
dies against AChRs were reported to bind to
AChRs on OHCs, resulting in a progressive
loss of AChRs that eventually affected their
functionality and decreased OHC electro-
motility.10 This cascade of events has been
found to induce apoptosis in all three rows of
OHCs, evolving into clinically evident hear-
ing loss in some cases.10
Hearing function and MG: The role of the
efferent auditory system
The functional aspects of the efferent audi-
tory system in MG patients have previously
been investigated using contralateral acoustic
stimulation (CAS).12 CAS produces physio-
logical suppression of otoacoustic emis-
sions13 by activating the medial
olivocochlear complex, providing efferent
feedback by releasing ACh from the olivoco-
chlear nerve fibres onto OHCs and thus
protecting the hair cells from noise of mod-
erate to high intensity.14,15 A reduced CAS
effect has been reported in patients with MG
compared with control subjects, suggesting a
possible role of progressive reduction of the
beta subunits of nicotinic AChRs, which has
been associated with the destruction of the
basal membrane and OHCs due to prolonged
exposure to autoantibodies.10,12
Evaluating hearing function in MG
Evaluation of hearing function in MG:
The role of the stapedial reflex
A number of studies between the mid 1970s
and early 1990s examined the stapedial reflex
(SR) inMG patients as an additional tool for
diagnosis and monitoring of the disorder.
The use of SR in MG was initially examined
by Blom,16 and the SR decay test (SRDT)
with a 1-minute sound stimulus of 500Hz
was subsequently proposed by Warren.17
Kramer18 measured the pattern of SR fatigue
in response to pulsed acoustic stimulation in
89MG patients, compared with the effects of
repetitive nerve stimulation and single-fibre
electromyography. The results revealed that
SR fatigue exceeded normal control values in
84% of MG patients, particularly in subjects
with mild forms of myasthenia.18 Yamane19
investigated the threshold and latency par-
ameters and the response pattern of the reflex
in 11 patients with MG, reporting an
unstable response pattern to 10-second tone
stimuli and a lengthened mean reflex latency.
Bischoff20 studied the decay and recovery of
SR amplitude in 19 patients with MG and
reported that the continuous prolonged
stimulation of the stapedial muscle could be
considered a practical and valid method for
the evaluation of MG patients. Smith20
studied the SRDT in 30 patients with sus-
pected MG, successfully measuring the reflex
in 17 patients. Of these, 41% exhibited
abnormal values.21 To´th22 reported a series
of 16 MG cases, finding that SR values were
increased in 93% of patients, while stapedial
exhaustion was observed in 71% of patients.
Moreover, after the administration of
a reversible cholinesterase inhibitor
(Mestinon), the reflex threshold decreased
and exhaustion occurred in only 50% of
cases.22 Taken together, these findings sug-
gest that examination of the stapedial reflex
in patients with MG may represent a useful
supplementary diagnostic and monitoring
tool.
Evaluation of hearing function in MG:
The role of otoacoustic emissions
While alteration of the SR has been exten-
sively documented in MG, there is
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increasing evidence that OHCs play a cen-
tral role in auditory alterations in the dis-
order. Several studies have produced
evidence of a reduction of both TEOAEs9
and DPOAEs10,12,23 in MG patients com-
pared with normal controls. Furthermore,
treatment with reversible ACh inhibitors has
been shown to increase amplitudes of
TEOAEs and DPOAEs, although not
always to the levels observed for healthy
controls.12,23
To´th9 measured TEOAEs in 29 ears of
MG patients, reporting significantly lower
TEOAE values in MG patients compared
with healthy controls. The administration of
a reversible cholinesterase inhibitor (pyrido-
stigmine bromide; Mestinon) resulted in a
significant increase in TEOAE amplitude,
although the amplitudes remained lower
than those of controls.9 Paludetti23 recorded
DPOAEs in 25 patients with MG, with
normal hearing, before and 1 h after admin-
istration of 60mg pyridostigmine bromide,
and compared the results with those of 25
control subjects. DPOAE amplitudes were
found to be significantly lower in MG
patients before the administration of the
drug, and were increased after drug admin-
istration, particularly for middle to high
frequencies. In accord with the findings
reported by To´th9, even after drug adminis-
tration, DPOAE values remained lower
among MG patients compared with con-
trols.23 As mentioned above, CAS is con-
sidered a useful additional test for
monitoring OHC in MG patients. Di
Girolamo12 recorded DPOAEs in 20 MG
subjects with and without CAS before and
1 h after administration of a reversible ACh
inhibitor. The results revealed no significant
DPOAE amplitude changes upon exposure
to contralateral noise before drug adminis-
tration. However, after drug administration,
CAS induced a significant decrease of
DPOAE amplitudes for middle frequen-
cies.12 Hamed10 investigated OHC function
in 16 MG patients 1 week and 2 months
after a myasthenic crisis or acute oropha-
ryngeal dysfunction. Comparison with
healthy controls revealed that MG patients
exhibited a significant reduction in TEOAE
amplitude at 1–2 kHz and a reduction of
DPOAE amplitude at 1–6 kHz. No changes
were observed among control subjects.10 In
all of the studies discussed above, substan-
tial variation was observed in the response
amplitudes for middle and high frequencies,
possibly due to a higher concentration of
ACh receptors in the basal and middle
cochlear turns.
The role of otolaryngologists
MG is a condition that requires a multi-
disciplinary approach. The pathophysio-
logical evidence described in the current
review typically precedes clinically evident
hearing loss, and MG is often associated
with hearing loss that is not noticed by the
patient. Thus, otolaryngologists play a cen-
tral role in identifying possible hearing
dysfunction and monitoring the progress of
hearing alterations in patients with a diag-
nosis of MG. Due to the involvement of
OHCs in MG, otoacoustic emissions repre-
sent the most relevant test for monitoring
hearing function, even if other examination
methods, such as PTA and Auditory
Brainstem Response (ABR) produce results
within the normal range. Besides a complete
clinical and audiological examination, tran-
sient evoked and distortion product OAE
should always be used at MG diagnosis, and
should be repeated over time. The onset of
associated symptoms such as tinnitus may
follow progressive hearing loss, and should
therefore always be investigated.24 The
studies reviewed above also support the use
of CAS, and evaluation of the responsive-
ness of the OHCs to the administration of an
acetylcholinesterase inhibitor by monitoring
OAE amplitude changes.
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The role of otolaryngologists: Our experience
The Tinnitus Unit at the Sapienza State
University, Policlinico Umberto I in Rome
has treated approximately 4,300 tinnitus
patients over the past 10 years.25 A case
study of a patient with MG and tinnitus
produced results that are consistent with the
findings of previous studies. PTA revealed a
bilateral sensorineural mild hearing loss for
high frequencies (avg 23.40 dBHL;
avg> 2 kHz 34.5; avg> 4kHz 41.66 dBHL).
A consistent reduction was found in mid and
high range amplitudes when recording base-
line TEOAE and DPOAE, compared with
controls. Following protocols reported in
previous studies,5,7,18 the results revealed a
significant increase of TEOAE amplitude at
2.8 and 4.0 kHz1h after administration of
60mg pyridostigmine bromide (Mestinon).
Amplitudes returned to baseline values after
24 hours. In contrast, no amplitude
changes were observed in DPOAEs after
drug administration. Measures of single
TEOAE frequencies before and after
drug administration were as follows:
1.0 kHz¼ 3.45dB (before), 1.60dB (after);
1.4 kHz¼ 4.65dB (before), 2.45dB (after);
2.0 kHz¼2.10dB (before), 2.35dB
(after); 2.8 kHz¼5.50dB (before), 2.20dB
(after); 4.0 kHz¼8.40dB (before), 0.95dB
(after). In addition, the signal to noise ratio
was higher than the minimum acceptable
value of 5 dB for all frequencies, with an
average of 9.45dB. TEAOE amplitudes rec-
orded before, 1 h and 24h after drug admin-
istration are shown in Figure 1.
Although CAS did not cause a reduc-
tion of TEOAE amplitudes under basal
conditions, we observed a clear CAS effect
after drug administration, as indicated by a
marked reduction of TEOAE amplitude, par-
ticularly for 2.8 and 4.0 kHz stimulation.
These findings, particularly the large
variation in amplitudes for middle and
high frequencies, are in accord with previous
reports, confirming that OAEs can play a
useful role in the early detection of MG-
related effects on the ACh-innervated audi-
tory system. These methods could be utilized
Figure 1. TEOAE amplitudes in a patient with MG before and after 60mg pyridostigmine bromide
(Mestinon) administration. Before drug administration, TEOAE amplitudes were reduced compared with
controls. After drug administration, a significant increase of TEOAE amplitudes was recorded, particularly for
the 2.8 and 4.0 kHz frequencies; amplitudes returned close to baseline values after 24 hours.
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for the assessment and monitoring of hear-
ing function in patients with MG.
Conclusion
Increasing evidence suggests that chronic
OHC dysfunction in patients with MG is
associated with the progressive loss of
AChRs on the basolateral portion of
OHCs. Taken together, the studies discussed
in this review contribute to the understand-
ing of the association between pathophysio-
logical alterations recorded in the inner ear
of MG patients and a subclinical or, in some
cases, clinically evident hearing disorder
Effective diagnosis and treatment thus
requires a multidisciplinary approach in
clinical management and follow up.
Hearing loss in patients with MG often
occurs at a subclinical stage, particularly
during the first decades of life. However,
chronic dysfunction of OHCs can result in a
progressive loss of hearing that is rarely
noticed by patients. These characteristics
suggest that hearing function should always
be assessed in patients with MG, particu-
larly via examination of OHCs with otoa-
coustic emissions, and, to a lesser extent, SR.
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